U.S. Banks Stock News

NasdaqGM:GUTS
NasdaqGM:GUTSMedical Equipment

Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift – Has The Bull Case Changed?

In May 2026, Fractyl Health reported first-quarter 2026 net income of US$9.22 million, reversing a prior-year loss, and secured authorization in the Netherlands to begin a Phase 1/2 first-in-human trial of RJVA-001, its Smart GLP-1 gene therapy candidate for type 2 diabetes. An important detail for investors is that this regulatory clearance makes Fractyl a dual clinical-stage company, advancing both its Revita procedure for post‑GLP‑1 weight maintenance and its Rejuva gene therapy platform...
NasdaqGS:PRGS
NasdaqGS:PRGSSoftware

Progress Software Award Spotlights Agentic RAG And Undervalued AI Potential

Progress Software (NasdaqGS:PRGS) has received a 2026 Artificial Intelligence Excellence Award for its Agentic RAG platform. The award recognizes the platform in the Retrieval Augmented Generation (RAG) category for its role in AI driven data solutions. Agentic RAG focuses on converting unstructured data into governed intelligence for enterprise use. For you as an investor, this award draws attention to how Progress Software is positioning itself around operational AI rather than only...
NYSE:VAL
NYSE:VALEnergy Services

Is Valaris (VAL) Trading Profitability for Revenue Stability After Its Narrowed Q1 2026 Loss?

Valaris Limited has reported past first-quarter 2026 results, with revenue of US$465.4 million versus US$620.7 million a year earlier and a net loss of US$16.4 million, compared to US$37.9 million previously. Despite the revenue decline, the company meaningfully narrowed its basic and diluted loss per share from continuing operations to US$0.24, down from US$0.53. We’ll now examine how the reduced net loss, alongside revenue pressure, may influence Valaris’ pre-existing investment narrative...
NasdaqGS:CLBT
NasdaqGS:CLBTSoftware

Cellebrite DI (CLBT) Profitability Turnaround Tests Bullish Growth Narratives

Cellebrite DI (NasdaqGS:CLBT) opened Q1 2026 with revenue of US$128.3 million and basic EPS of US$0.04, alongside net income of US$10.9 million, with the trailing twelve months showing revenue of US$496.4 million and basic EPS of US$0.29 tied to net income of US$71.4 million. Over recent quarters, revenue has moved from US$107.5 million and basic EPS of US$0.07 in Q1 2025 to around US$128 million and basic EPS in the US$0.08 range through late 2025, then to US$128.3 million and basic EPS of...